Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKIL15
- Development stage
- Unknown
- Lead developer
- Fundación de Investigación Biomédica. Instituto de Investigación Sanitaria d
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal
01
Overview
NKIL15 is an autologous natural killer (NK) cell therapy product that has been stimulated with interleukin-15 (IL-15) to enhance its anti-tumor potency. Developed by the Hospital Universitario La Paz, it is currently being evaluated in Phase I/II clinical trials for the treatment of recurrent or refractory high-grade central nervous system (CNS) tumors in children, adolescents, and young adults. The therapy is administered directly into the cerebrospinal fluid via intraventricular or intrathecal routes. The stimulation with IL-15 is designed to improve the proliferation, survival, and cytotoxic capabilities of the NK cells, allowing them to more effectively target and eliminate malignant cells within the CNS, bypassing the blood-brain barrier.
- Other names
- IL-15-stimulated NK cellsIL15-stimulated NK cellsIL 15-stimulated NK cellsIL-15-activated NK cellsIL15-activated NK cellsIL 15-activated NK cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on NKIL15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKIL15.